Photo: Pfizer BioNTech-Pfizer said Wednesday their vaccine showed 100 percent efficacy against the coronavirus in 12 to 15 year olds, as they eye approval for adolescents to get the jabs before the next school year. Phase 3 trials carried out on 2,260 adolescents in the United States "demonstrated 100 percent efficacy and robust antibody responses", the companies said in a statement. Chief executive of German company BioNTech said the results showing high protection for teens were "very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant". The BioNTech/Pfizer shot is based on novel mRNA technology and was the first Covid-19 vaccine to be approved in the West late last year. | via Agence France-Presse